Aegerion gains $22.5M in VC

Aegerion Pharmaceuticals of Bridgewater, NJ has rounded up $22.5 million in its first round of venture capital. Aegerion's lead compounds reduce levels of LDL cholesterol, a major target in the drug development world. Aegerion CEO Jerry Wisler spent 20 years at Merck, including a stint as vice president of the atherosclerosis franchise, with responsibility for Zocor.

- read this release for more